Want to see NNOX full AI Analyst Report?
NNOX Stock Chart & Stats
$0.88
-$0.01(-1.14%)
At close: 4:00 PM EDT
$0.88
-$0.01(-1.14%)
Day’s Range― - ―
52-Week Range$0.36 - $4.71
Previous Close$0.89
Volume1.06M
Average Volume (3M)1.06M
Market Cap
$32.48M
Enterprise Value$57.82M
Total Cash (Recent Filing)$31.02M
Total Debt (Recent Filing)$7.73M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 19, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding78,588,640
10 Day Avg. Volume955,209
30 Day Avg. Volume1,057,816
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)1.30
Price to Sales (P/S)13.93
P/FCF Ratio-4.03
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue3.70
Enterprise Value/Gross Profit-1.09
Enterprise Value/Ebitda-0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$20.87M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth shows that Nanox is converting its imaging, teleradiology, AI and software offerings into expanding commercial activity. Continued top-line progress can improve operating leverage over time, although the company still needs to translate growth into sustainable margins and cash generation.
Commercialization And ReimbursementActual patient scans and paid reimbursement provide evidence that the Imaging Network is moving beyond deployment toward an operating healthcare service. This creates a foundation for repeat utilization and site-level revenue growth as reimbursement, payer coverage and customer adoption expand.
Low LeverageVery low leverage limits interest and default pressure relative to a more highly indebted business, preserving some financial flexibility while Nanox commercializes its platform. This is a meaningful structural strength, even though ongoing losses and shrinking equity weaken the overall balance sheet.
Bears Say
Going-Concern Liquidity RiskThe projected cash position and explicit going-concern warning indicate that Nanox may need substantial additional financing to maintain current operations. If capital is unavailable, management may have to delay development, reduce commercialization activity or grant product rights to others.
Severe UnprofitabilityPersistently negative gross profit means revenue is not yet covering the direct cost of delivering the company’s offerings, while large operating and net losses show that scale has not produced financial leverage. This weak economics profile threatens self-funding and requires continued cost or revenue improvement.
Delayed CommercializationOperational friction at imaging centers can lengthen the time between signed opportunities and productive installations, slowing customer conversion and revenue realization. Delays also make forecasting more difficult and can postpone the utilization gains needed to improve margins and validate the deployment model.
Nano-X Imaging News
NNOX FAQ
What was Nano-X Imaging’s price range in the past 12 months?
Nano-X Imaging lowest stock price was $0.36 and its highest was $4.71 in the past 12 months.
What is Nano-X Imaging’s market cap?
Nano-X Imaging’s market cap is $32.48M.
When is Nano-X Imaging’s upcoming earnings report date?
Nano-X Imaging’s upcoming earnings report date is Nov 19, 2026 which is in 27 days.
How were Nano-X Imaging’s earnings last quarter?
Nano-X Imaging released its earnings results on Sep 09, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.162 by -$0.628.
Is Nano-X Imaging overvalued?
According to Wall Street analysts Nano-X Imaging’s price is currently Overvalued.
Does Nano-X Imaging pay dividends?
Nano-X Imaging does not currently pay dividends.
What is Nano-X Imaging’s EPS estimate?
Nano-X Imaging’s EPS estimate is -0.15.
How many shares outstanding does Nano-X Imaging have?
Nano-X Imaging has 78,588,640 shares outstanding.
What happened to Nano-X Imaging’s price movement after its last earnings report?
Nano-X Imaging reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.162. Following the earnings report the stock price went down -16.129%.
Which hedge fund is a major shareholder of Nano-X Imaging?
Currently, no hedge funds are holding shares in NNOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nano-X Imaging Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
NNOX Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 73.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $196.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.44%
12-Months-Change
Fundamentals
Return on Equity
-94.35%
Trailing 12-Months
Asset Growth
-50.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nano-X Imaging
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.
NNOX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained substantial commercialization, deployment, clinical, reimbursement, partnership, and cost-reduction progress, including 37% year-over-year revenue growth and $8.5 million of post-quarter-end financing. However, these positives were offset by commercialization delays, a $40.7 million impairment, materially higher GAAP net loss, negative gross loss margins, increased operating expenses, a lower cash balance, and the need for continued fundraising. Overall sentiment was cautiously balanced.View all NNOX earnings summariesTechnical Analysis
Koninklijke Philips
―
Varex Imaging
―
Hyperfine
―
QT Imaging Holdings
―
GE Healthcare Technologies Inc
―
Ownership Overview
1.17% Insiders
2.18% Mutual Funds
0.12% Other Institutional Investors
96.24% Public Companies and
Individual Investors